The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

In the ever-evolving field of longevity and anti-aging research, chemical sciences are making significant strides, ...

As CTO, Mr. Beneski will oversee Allogene's technical operations, leveraging his extensive expertise in biologics ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati ...

In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches—gene therapy and ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...